It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mitochondrial dysfunction and lysosomal dysfunction have been implicated in Parkinson’s disease (PD), but the links between these dysfunctions in PD pathogenesis are still largely unknown. Here we report that cytosolic dsDNA of mitochondrial origin escaping from lysosomal degradation was shown to induce cytotoxicity in cultured cells and PD phenotypes in vivo. The depletion of PINK1, GBA and/or ATP13A2 causes increases in cytosolic dsDNA of mitochondrial origin and induces type I interferon (IFN) responses and cell death in cultured cell lines. These phenotypes are rescued by the overexpression of DNase II, a lysosomal DNase that degrades discarded mitochondrial DNA, or the depletion of IFI16, which acts as a sensor for cytosolic dsDNA of mitochondrial origin. Reducing the abundance of cytosolic dsDNA by overexpressing human DNase II ameliorates movement disorders and dopaminergic cell loss in gba mutant PD model zebrafish. Furthermore, IFI16 and cytosolic dsDNA puncta of mitochondrial origin accumulate in the brain of patients with PD. These results support a common causative role for the cytosolic leakage of mitochondrial DNA in PD pathogenesis.
Mitochondrial and lysosomal dysfunction are central to Parkinson’s disease (PD) pathogenesis. Here, the authors show mitochondrial dsDNA in the cytosol in cellular and Zebrafish models of PD induces cytotoxicity and neurodegeneration; knock-down of IFI16, a cytosolic dsDNA sensor, rescues cytotoxicity, as does overexpression of lysosomal DNAse II.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Niigata University, Department of Neuroscience of Disease, Brain Research Institute, Niigata, Japan (GRID:grid.260975.f) (ISNI:0000 0001 0671 5144); Niigata University, Department of Neuroscience of Disease, Center for Transdisciplinary Research, Niigata, Japan (GRID:grid.260975.f) (ISNI:0000 0001 0671 5144)
2 Niigata University, Department of Pathology, Brain Research Institute, Niigata, Japan (GRID:grid.260975.f) (ISNI:0000 0001 0671 5144)
3 Niigata University, Department of Neuroscience of Disease, Brain Research Institute, Niigata, Japan (GRID:grid.260975.f) (ISNI:0000 0001 0671 5144)
4 University of Miyazaki, Frontier Science Research Center, Miyazaki, Japan (GRID:grid.410849.0) (ISNI:0000 0001 0657 3887)
5 Niigata University, Department of Neurology, Brain Research Institute, Niigata, Japan (GRID:grid.260975.f) (ISNI:0000 0001 0671 5144)